2013 Q3 Form 10-Q Financial Statement
#000144530513002083 Filed on August 09, 2013
Income Statement
Concept | 2013 Q3 | 2013 Q2 | 2012 Q2 |
---|---|---|---|
Revenue | $3.943M | $6.974M | $22.91M |
YoY Change | -85.03% | -69.56% | -12.07% |
Cost Of Revenue | $494.0K | $3.631M | $5.829M |
YoY Change | -92.28% | -37.71% | -17.97% |
Gross Profit | $3.449M | $3.343M | $17.08M |
YoY Change | -82.71% | -80.43% | -9.86% |
Gross Profit Margin | 87.47% | 47.94% | 74.56% |
Selling, General & Admin | $5.832M | $7.169M | $6.789M |
YoY Change | -26.26% | 5.6% | -26.81% |
% of Gross Profit | 169.09% | 214.45% | 39.75% |
Research & Development | $6.831M | $8.624M | $15.65M |
YoY Change | -51.86% | -44.89% | 4.58% |
% of Gross Profit | 198.06% | 257.97% | 91.63% |
Depreciation & Amortization | $2.610M | $2.590M | $3.230M |
YoY Change | -16.88% | -19.81% | 16.19% |
% of Gross Profit | 75.67% | 77.48% | 18.91% |
Operating Expenses | $13.16M | $19.42M | $28.27M |
YoY Change | -53.83% | -31.29% | -9.82% |
Operating Profit | -$9.214M | -$12.45M | -$5.359M |
YoY Change | 327.37% | 132.32% | -56.78% |
Interest Expense | $10.00K | $20.00K | $70.00K |
YoY Change | -83.33% | -71.43% | 0.0% |
% of Operating Profit | |||
Other Income/Expense, Net | $22.00K | $183.0K | $157.0K |
YoY Change | -51.11% | 16.56% | 685.0% |
Pretax Income | -$9.227M | -$12.62M | -$5.442M |
YoY Change | 331.17% | 131.84% | 4.55% |
Income Tax | $35.00K | -$12.00K | $77.00K |
% Of Pretax Income | |||
Net Earnings | -$9.262M | -$12.61M | -$5.519M |
YoY Change | 301.13% | 128.39% | 9.5% |
Net Earnings / Revenue | -234.9% | -180.74% | -24.09% |
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$243.0K | -$331.3K | -$152.1K |
COMMON SHARES | |||
Basic Shares Outstanding | 38.09M shares | 38.03M shares | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2013 Q3 | 2013 Q2 | 2012 Q2 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $29.92M | $37.90M | $51.40M |
YoY Change | -40.63% | -26.26% | 10.06% |
Cash & Equivalents | $26.91M | $32.39M | $16.69M |
Short-Term Investments | $3.009M | $5.512M | $34.70M |
Other Short-Term Assets | $1.900M | $2.300M | $5.100M |
YoY Change | -63.46% | -54.9% | 112.5% |
Inventory | $2.101M | $1.332M | $4.200M |
Prepaid Expenses | |||
Receivables | $2.688M | $1.591M | $8.100M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $36.64M | $43.11M | $68.80M |
YoY Change | -51.01% | -37.34% | 6.67% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $13.81M | $15.52M | $22.10M |
YoY Change | -30.61% | -29.77% | 2.31% |
Goodwill | $3.241M | $3.241M | |
YoY Change | |||
Intangibles | $10.40M | $11.25M | |
YoY Change | |||
Long-Term Investments | $1.100M | $1.000M | $6.100M |
YoY Change | -69.44% | -83.61% | -76.36% |
Other Assets | $361.0K | $363.0K | $2.800M |
YoY Change | -90.24% | -87.04% | 3.7% |
Total Long-Term Assets | $29.79M | $32.50M | $48.90M |
YoY Change | -32.6% | -33.54% | -31.7% |
TOTAL ASSETS | |||
Total Short-Term Assets | $36.64M | $43.11M | $68.80M |
Total Long-Term Assets | $29.79M | $32.50M | $48.90M |
Total Assets | $66.44M | $75.61M | $117.7M |
YoY Change | -44.17% | -35.76% | -13.52% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.490M | $1.545M | $4.300M |
YoY Change | -76.35% | -64.07% | -44.16% |
Accrued Expenses | $2.140M | $3.900M | $11.70M |
YoY Change | -82.31% | -66.67% | -5.65% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $9.218M | $11.15M | $19.60M |
YoY Change | -55.47% | -43.14% | -20.33% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $5.183M | $3.783M | $5.500M |
YoY Change | -2.21% | -31.22% | 17.02% |
Total Long-Term Liabilities | $5.183M | $3.783M | $5.500M |
YoY Change | -2.21% | -31.22% | 17.02% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $9.218M | $11.15M | $19.60M |
Total Long-Term Liabilities | $5.183M | $3.783M | $5.500M |
Total Liabilities | $14.40M | $14.93M | $25.20M |
YoY Change | -44.61% | -40.76% | -13.99% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$247.0M | -$237.8M | |
YoY Change | |||
Common Stock | $4.000K | $4.000K | |
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $50.87M | $59.47M | $92.50M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $66.44M | $75.61M | $117.7M |
YoY Change | -44.17% | -35.76% | -13.52% |
Cashflow Statement
Concept | 2013 Q3 | 2013 Q2 | 2012 Q2 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$9.262M | -$12.61M | -$5.519M |
YoY Change | 301.13% | 128.39% | 9.5% |
Depreciation, Depletion And Amortization | $2.610M | $2.590M | $3.230M |
YoY Change | -16.88% | -19.81% | 16.19% |
Cash From Operating Activities | -$8.530M | -$7.070M | -$3.880M |
YoY Change | 120.41% | 82.22% | -49.15% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $190.0K | -$590.0K | -$440.0K |
YoY Change | -337.5% | 34.09% | -86.67% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $2.850M | $8.810M | -$5.780M |
YoY Change | -76.68% | -252.42% | -47.69% |
Cash From Investing Activities | $3.040M | $8.220M | -$6.220M |
YoY Change | -74.96% | -232.15% | -56.66% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 10.00K | 20.00K | 200.0K |
YoY Change | -98.33% | -90.0% | -77.78% |
NET CHANGE | |||
Cash From Operating Activities | -8.530M | -7.070M | -3.880M |
Cash From Investing Activities | 3.040M | 8.220M | -6.220M |
Cash From Financing Activities | 10.00K | 20.00K | 200.0K |
Net Change In Cash | -5.480M | 1.170M | -9.900M |
YoY Change | -161.78% | -111.82% | -53.04% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$8.530M | -$7.070M | -$3.880M |
Capital Expenditures | $190.0K | -$590.0K | -$440.0K |
Free Cash Flow | -$8.720M | -$6.480M | -$3.440M |
YoY Change | 130.08% | 88.37% | -20.55% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2013Q2 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1545000 | USD |
CY2012Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
3654000 | USD |
CY2012Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
7545000 | USD |
CY2013Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1591000 | USD |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-377000 | USD | |
us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
48000 | USD | |
CY2012Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6948000 | USD |
us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
0 | USD | |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
3541000 | USD | |
CY2013Q2 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
3900000 | USD |
CY2012Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
34172000 | USD |
CY2013Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
37084000 | USD |
CY2012Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-136000 | USD |
CY2013Q2 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
106000 | USD |
CY2013Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
297144000 | USD |
CY2012Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
294128000 | USD |
CY2013Q2 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
150000 | USD |
CY2012Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
150000 | USD |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1806000 | USD | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1687000 | USD | |
CY2012Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9365000 | shares |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6898000 | shares | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9365000 | shares | |
CY2013Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6898000 | shares |
CY2013Q2 | us-gaap |
Asset Retirement Obligation
AssetRetirementObligation
|
300000 | USD |
us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
15000 | USD | |
CY2012Q4 | us-gaap |
Assets
Assets
|
99965000 | USD |
CY2013Q2 | us-gaap |
Assets
Assets
|
75606000 | USD |
CY2013Q2 | us-gaap |
Assets Current
AssetsCurrent
|
43107000 | USD |
CY2012Q4 | us-gaap |
Assets Current
AssetsCurrent
|
59769000 | USD |
CY2013Q2 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
30090000 | USD |
CY2012Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
41873000 | USD |
CY2013Q2 | us-gaap |
Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
|
30550000 | USD |
CY2012Q4 | us-gaap |
Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
|
41936000 | USD |
CY2013Q2 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
0 | USD |
CY2012Q4 | us-gaap |
Available For Sale Securities Gross Unrealized Losses1
AvailableForSaleSecuritiesGrossUnrealizedLosses1
|
0 | USD |
CY2013Q2 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
460000 | USD |
CY2012Q4 | us-gaap |
Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
|
63000 | USD |
CY2013Q2 | us-gaap |
Cash
Cash
|
8400000 | USD |
CY2012Q4 | us-gaap |
Cash
Cash
|
7200000 | USD |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
32003000 | USD |
CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
32392000 | USD |
CY2011Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
25762000 | USD |
CY2012Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16693000 | USD |
us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
4544000 | USD | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-9069000 | USD | |
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
389000 | USD | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.59 | ||
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
87000 | USD | |
CY2012Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
CY2013Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | USD |
CY2012Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | USD |
CY2013Q2 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
2365000 | USD |
CY2012Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
2186000 | USD |
CY2012Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
1299000 | USD |
CY2013Q2 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
1207000 | USD |
CY2013Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
184895 | shares |
CY2013Q2 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, accounts receivable and restricted cash. Cash and cash equivalents, marketable securities and restricted cash are invested through banks and other financial institutions in the United States, as well as in other foreign countries. Such deposits may be in excess of insured limits.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's top </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> customers accounted for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">73%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">85%</font><font style="font-family:inherit;font-size:10pt;"> of our total revenues for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2013</font><font style="font-family:inherit;font-size:10pt;">. Accounts receivable balances for the top </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">five</font><font style="font-family:inherit;font-size:10pt;"> customers were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">70%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">84%</font><font style="font-family:inherit;font-size:10pt;"> of total balances as of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2013</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2012</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credit risk with respect to accounts receivable exists to the extent of amounts presented in the condensed consolidated financial statements. The Company estimates an allowance for doubtful accounts through specific identification of potentially uncollectible accounts receivable based on an analysis of its accounts receivable aging. Uncollectible accounts receivable are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from its estimates and could be material to its consolidated financial position, results of operations, and cash flows.</font></div></div> | ||
CY2012Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
5829000 | USD |
us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
18471000 | USD | |
us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
9296000 | USD | |
CY2013Q2 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
3631000 | USD |
CY2013Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.33 | |
CY2012Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.15 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.36 | ||
us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
0 | USD | |
us-gaap |
Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
|
164000 | USD | |
CY2013Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3335000 | USD |
CY2012Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
3495000 | USD |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-77000 | USD | |
us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
274000 | USD | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-141000 | USD | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-109000 | USD | |
CY2013Q2 | us-gaap |
Goodwill
Goodwill
|
3241000 | USD |
CY2012Q4 | us-gaap |
Goodwill
Goodwill
|
3241000 | USD |
CY2012Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-5442000 | USD |
CY2013Q2 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-12617000 | USD |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-12735000 | USD | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
-22305000 | USD | |
CY2012Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
77000 | USD |
CY2013Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-12000 | USD |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-6051000 | USD | |
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-2108000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-5954000 | USD | |
us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-10793000 | USD | |
CY2013Q2 | us-gaap |
Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
|
600000 | USD |
CY2013Q2 | us-gaap |
Marketable Securities
MarketableSecurities
|
5512000 | USD |
CY2012Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
13524000 | USD |
CY2013Q2 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
1017000 | USD |
CY2012Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
3623000 | USD |
CY2013Q2 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
24000000 | USD |
CY2012Q4 | us-gaap |
Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
|
24800000 | USD |
us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-234000 | USD | |
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-160000 | USD | |
us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-2596000 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-287000 | USD | |
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
30000 | USD | |
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
-3209000 | USD | |
us-gaap |
Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
|
798000 | USD | |
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
409000 | USD | |
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
38000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2799000 | USD | |
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-3116000 | USD | |
us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
-400000 | USD | |
us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
0 | USD | |
CY2012Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
12934000 | USD |
CY2013Q2 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
11247000 | USD |
CY2012Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
662000 | USD |
CY2013Q2 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
719000 | USD |
CY2013Q2 | us-gaap |
Inventory Net
InventoryNet
|
1332000 | USD |
CY2012Q4 | us-gaap |
Inventory Net
InventoryNet
|
1302000 | USD |
CY2013Q2 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
458000 | USD |
CY2012Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
588000 | USD |
CY2013Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
155000 | USD |
CY2012Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
52000 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
149000 | USD | |
CY2012Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
74000 | USD |
CY2013Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
16000 | USD |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
43000 | USD | |
CY2012Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
99965000 | USD |
CY2013Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
75606000 | USD |
CY2012Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16283000 | USD |
CY2013Q2 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
11145000 | USD |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Codexis, Inc. (the "Company") was incorporated in the state of Delaware in January 2002. The Company engineers enzymes for pharmaceutical, biofuel and chemical production. Its proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing.</font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. There are currently over </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50</font><font style="font-family:inherit;font-size:10pt;"> pharmaceutical firms using its technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also continues to develop its CodeXyme</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes to convert non-food plant material, which the Company calls cellulosic biomass, into affordable sugars, which can then be converted into renewable fuels and chemicals. The Company is also developing its own manufacturing process for CodeXol</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> detergent alcohols, which are bio-based chemicals. Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products such as shampoos, liquid soaps and laundry detergents. The Company is seeking collaboration partners to assist it with the development and commercialization of CodeXyme</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes and CodeXol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> detergent alcohols, and the Company is also exploring other strategic options with respect to these products and technologies. On July 30, 2013, the Company received a notice (the "Dyadic notice") from Dyadic International, Inc. (“Dyadic”) asserting that Dyadic believed the Company to be in breach of the parties' November 14, 2008 license agreement (the "Dyadic license agreement") and that Dyadic would terminate the Dyadic license agreement unless the Company cured such breach within </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;"> days of notice. The Company licenses Dyadic's C-1 based proprietary fungal expression technology from Dyadic under the Dyadic license agreement and uses the strain to engineer enzymes that are used in the Company's CodeXyme</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> cellulase enzymes. The Company's receipt of the Dyadic notice may interfere with its ability to find a collaboration partner for its CodeXyme</font><font style="font-family:inherit;font-size:7pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">cellulase enzyme program and the Company's strategic options in respect of this program may be limited until the matter is resolved. For a further discussion of the Dyadic notice and the potential impact the Dyadic notice and the termination of the license agreement would have on Codexis and its businesses, please see the Note 13 for subsequent events.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assists customers in discovering or enhancing enzymes variants by applying its CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> directed evolution technology platform, which introduces genetic mutations into microorganisms, giving rise to changes in the enzymes that they produce. Once the Company identifies potentially beneficial mutations, it tests combinations of these mutations until it has created variant enzymes that exhibit marketable performance characteristics superior to competitive products. This process allows the Company to make continuous, efficient improvements to the performance of its enzymes. </font></div><div style="line-height:120%;padding-bottom:10px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these Notes to condensed consolidated financial statements, the “Company” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div></div> | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
287000 | USD | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
281000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-6228000 | USD | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
10668000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-3292000 | USD | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-10560000 | USD | |
CY2013Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12605000 | USD |
CY2013Q2 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
27131000 | USD |
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | operating_segment | |
us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | reporting_unit | |
CY2012Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
28268000 | USD |
us-gaap |
Operating Expenses
OperatingExpenses
|
40535000 | USD | |
us-gaap |
Operating Expenses
OperatingExpenses
|
66654000 | USD | |
CY2013Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
19424000 | USD |
CY2013Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12450000 | USD |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12609000 | USD | |
CY2012Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5359000 | USD |
CY2012Q4 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
31821000 | USD |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-13009000 | USD | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-22228000 | USD | |
CY2012Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5519000 | USD |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-22080000 | USD | |
CY2013Q2 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
18930000 | USD |
CY2013Q2 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
1438000 | USD |
CY2013Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
2677000 | USD |
CY2013Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
3047000 | USD |
CY2013Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
3031000 | USD |
CY2013Q2 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
2947000 | USD |
CY2013Q2 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
5790000 | USD |
CY2013Q2 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
363000 | USD |
CY2012Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2237000 | USD |
CY2013Q2 | us-gaap |
Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
|
50000 | USD |
us-gaap |
Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
|
-471000 | USD | |
us-gaap |
Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
|
242000 | USD | |
CY2012Q2 | us-gaap |
Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
|
-337000 | USD |
CY2012Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | USD |
CY2013Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
32000 | USD |
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | USD | |
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
155000 | USD | |
CY2012Q2 | us-gaap |
Other Expenses
OtherExpenses
|
157000 | USD |
us-gaap |
Other Expenses
OtherExpenses
|
275000 | USD | |
us-gaap |
Other Expenses
OtherExpenses
|
268000 | USD | |
CY2013Q2 | us-gaap |
Other Expenses
OtherExpenses
|
183000 | USD |
CY2012Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
3943000 | USD |
CY2013Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
3783000 | USD |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
19141000 | USD | |
us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2551000 | USD | |
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
641000 | USD | |
CY2013Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2280000 | USD |
CY2012Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
5395000 | USD |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
4964000 | USD | |
us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
10909000 | USD | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
281000 | USD | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
287000 | USD | |
CY2013Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
52559000 | USD |
CY2012Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
50794000 | USD |
CY2012Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
16650000 | USD |
CY2013Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
15520000 | USD |
us-gaap |
Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
|
242000 | USD | |
us-gaap |
Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
|
30480000 | USD | |
us-gaap |
Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
|
4370000 | USD | |
CY2012Q2 | us-gaap |
Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
|
15868000 | USD |
CY2013Q2 | us-gaap |
Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
|
2026000 | USD |
CY2013Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8624000 | USD |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15946000 | USD | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
31999000 | USD | |
CY2012Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15650000 | USD |
CY2013Q2 | us-gaap |
Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
|
1111000 | USD |
CY2012Q4 | us-gaap |
Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
|
1511000 | USD |
CY2013Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-237783000 | USD |
CY2012Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-215556000 | USD |
CY2013Q2 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
0 | USD |
CY2012Q2 | us-gaap |
Revenue From Grants
RevenueFromGrants
|
259000 | USD |
us-gaap |
Revenue From Grants
RevenueFromGrants
|
0 | USD | |
us-gaap |
Revenue From Grants
RevenueFromGrants
|
1616000 | USD | |
us-gaap |
Revenues
Revenues
|
54045000 | USD | |
CY2012Q2 | us-gaap |
Revenues
Revenues
|
22909000 | USD |
us-gaap |
Revenues
Revenues
|
18455000 | USD | |
CY2013Q2 | us-gaap |
Revenues
Revenues
|
6974000 | USD |
CY2013Q2 | us-gaap |
Sales Revenue Goods Gross
SalesRevenueGoodsGross
|
4948000 | USD |
us-gaap |
Sales Revenue Goods Gross
SalesRevenueGoodsGross
|
14085000 | USD | |
CY2012Q2 | us-gaap |
Sales Revenue Goods Gross
SalesRevenueGoodsGross
|
6782000 | USD |
us-gaap |
Sales Revenue Goods Gross
SalesRevenueGoodsGross
|
21949000 | USD | |
CY2012Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1907000 | USD |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
15293000 | USD | |
us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
16184000 | USD | |
CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
78440000 | USD |
CY2013Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
59471000 | USD |
CY2013Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1262000 | USD |
CY2013Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
7169000 | USD |
CY2012Q2 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
6789000 | USD |
CY2012Q3 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
800000 | USD |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2735000 | USD | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3077000 | USD | |
CY2012Q2 | us-gaap |
Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
|
-337000 | USD |
CY2013Q2 | us-gaap |
Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
|
50000 | USD |
us-gaap |
Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
|
-636000 | USD | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company's management regularly assesses these estimates which primarily affect revenue recognition, the valuation of marketable securities and accounts receivable, intangible assets, goodwill arising out of business acquisitions, inventories, accrued liabilities, common stock, and stock options and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</font></div></div> | ||
CY2013Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
38060000 | shares |
CY2012Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36296000 | shares |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
37951000 | shares | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36177000 | shares | |
cdxs |
Classof Warrantor Right Exercise Priceof Warrantsor Rights Expired
ClassofWarrantorRightExercisePriceofWarrantsorRightsExpired
|
5.96 | ||
cdxs |
Comprehensive Loss
ComprehensiveLoss
|
-21986000 | USD | |
cdxs |
Comprehensive Loss
ComprehensiveLoss
|
-13480000 | USD | |
CY2013Q2 | cdxs |
Comprehensive Loss
ComprehensiveLoss
|
-12555000 | USD |
CY2012Q2 | cdxs |
Comprehensive Loss
ComprehensiveLoss
|
-5856000 | USD |
CY2011 | cdxs |
Contingent Revenue From Grant
ContingentRevenueFromGrant
|
500000 | USD |
CY2012Q2 | cdxs |
Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
|
0 | USD |
cdxs |
Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
|
165000 | USD | |
CY2013Q2 | cdxs |
Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
|
0 | USD |
cdxs |
Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
|
0 | USD | |
cdxs |
Marketable Securities Included In Non Current Asset
MarketableSecuritiesIncludedInNonCurrentAsset
|
P1Y | ||
cdxs |
Maturity Date Of Highly Liquid Investments
MaturityDateOfHighlyLiquidInvestments
|
P3M | ||
cdxs |
Noncash Transfer Transferof Other Assetsto Propertyand Equipment
NoncashTransferTransferofOtherAssetstoPropertyandEquipment
|
0 | USD | |
cdxs |
Noncash Transfer Transferof Other Assetsto Propertyand Equipment
NoncashTransferTransferofOtherAssetstoPropertyandEquipment
|
1912000 | USD | |
CY2012Q4 | cdxs |
Number Of Marketable Securities
NumberOfMarketableSecurities
|
0 | security |
CY2013Q2 | cdxs |
Number Of Marketable Securities
NumberOfMarketableSecurities
|
0 | Securities |
cdxs |
Number Of Pharmaceutical Firms Using Technology
NumberOfPharmaceuticalFirmsUsingTechnology
|
50 | Entity | |
cdxs |
Number Revenue Recognition Criteria
NumberRevenueRecognitionCriteria
|
4 | Criteria | |
cdxs |
Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
|
10500000 | USD | |
cdxs |
Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
|
0 | USD | |
CY2012Q4 | cdxs |
Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
|
16622000 | USD |
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001200375 | ||
CY2013Q2 | cdxs |
Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
|
15475000 | USD |
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2013 | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2013-06-30 | ||
CY2013Q3 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
38088637 | shares |
dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
CODEXIS INC |